TY - JOUR
T1 - Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial
AU - Jatoi, Aminah
AU - Egner, James
AU - Loprinzi, Charles L.
AU - Sloan, Jeff A.
AU - Novotny, Paul J.
AU - Dakhil, Shaker R.
AU - Mailliard, James A.
AU - Klee, George G.
AU - Krook, James E.
N1 - Funding Information:
Received: 17 December 2003 Accepted: 2 March 2004 Published online: 24 July 2004 © Springer-Verlag 2004 This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic, and was supported in part by Public Health Service grants: CA-25224, CA-37404, CA-15083, CA-63826, CA-63849, CA-35269, CA-35195, CA-35113, CA-60276, CA-52352, CA-35101, CA-35103, CA-63848, CA-35272, and CA-37417.
PY - 2004/9
Y1 - 2004/9
N2 - Background: Interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) have been implicated in the cancer anorexia/weight loss syndrome. However, previous smaller studies have yielded conflicting results as to whether circulating, serum concentrations of these cytokines are in fact elevated. As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome. Methods: Patients with incurable cancer with anorexia and/or weight loss were eligible. All underwent weekly weight measurements and appetite assessment for the first month and then monthly assessments thereafter. Serum was obtained at baseline and at 1 month, and all three cytokines were measured with the Immunolite assay. Results: A total of 118 patients participated. At baseline, 99%, 54%, and 47% of patients' samples had undetectable IL-1β, TNFα, and IL-6, respectively. Similar results were obtained at 1 month. No correlations were observed between serum cytokine concentrations and changes in weight or appetite. Baseline serum IL-6 predicted a diminished survival but only after adjustment for age and cancer site. Conclusion: Serum concentrations of IL-1β, TNFα, and IL-6, as measured in this study, provide data of limited clinical value for patients with the cancer anorexia/weight loss syndrome.
AB - Background: Interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and interleukin-6 (IL-6) have been implicated in the cancer anorexia/weight loss syndrome. However, previous smaller studies have yielded conflicting results as to whether circulating, serum concentrations of these cytokines are in fact elevated. As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome. Methods: Patients with incurable cancer with anorexia and/or weight loss were eligible. All underwent weekly weight measurements and appetite assessment for the first month and then monthly assessments thereafter. Serum was obtained at baseline and at 1 month, and all three cytokines were measured with the Immunolite assay. Results: A total of 118 patients participated. At baseline, 99%, 54%, and 47% of patients' samples had undetectable IL-1β, TNFα, and IL-6, respectively. Similar results were obtained at 1 month. No correlations were observed between serum cytokine concentrations and changes in weight or appetite. Baseline serum IL-6 predicted a diminished survival but only after adjustment for age and cancer site. Conclusion: Serum concentrations of IL-1β, TNFα, and IL-6, as measured in this study, provide data of limited clinical value for patients with the cancer anorexia/weight loss syndrome.
KW - Cancer anorexia/weight loss syndrome
KW - Cytokines
KW - Interleukin-1 beta
KW - Interleukin-6
KW - Tumor necrosis factor alpha
UR - http://www.scopus.com/inward/record.url?scp=4644301742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644301742&partnerID=8YFLogxK
U2 - 10.1007/s00520-004-0624-3
DO - 10.1007/s00520-004-0624-3
M3 - Article
C2 - 15278681
AN - SCOPUS:4644301742
SN - 0941-4355
VL - 12
SP - 640
EP - 644
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 9
ER -